A year into SPAC merger, Gemini restructures pipeline with 20% of staff, leadership on the chopping block
Gemini Therapeutics jumped to Nasdaq in a SPAC deal about a year ago, but on Tuesday announced a significant change in direction.
The biotech will undergo a corporate restructuring to focus on its clinical stage candidates, dropping all research and discovery programs and laying off 20% of its staff, it said in a Tuesday morning release. Gemini will attempt to reposition itself to better fund a pivotal study for its geographic atrophy program, dubbed GEM103.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.